Roche to increase payroll in Switzerland by 1.4 percent
Basel, 25 November 2014
Roche is increasing the payroll for its workforce of over 13,000 in Switzerland by 1.4 percent with effect from 1 April 2015. This latest increase acknowledges the workforce’s outstanding dedication in a challenging market environment in Europe and Switzerland. It also takes into account the salaries and wages for comparable employment, and increases in the cost of living.
Over recent weeks the company has been negotiating the 2015 payroll increase with the Roche Employees’ Association (AVR in Basel and Rotkreuz) and the Roche Basel Works Council (AKR). Unfortunately no consensus could be reached between Roche and the employee representatives regarding the payroll increase. The negotiations were conducted by all parties in a fair, focused and constructive atmosphere.
The 1.4 percent payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2015.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.